Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
From MaRDI portal
Publication:2912356
Recommendations
- A Bayesian Approach to the Design of Phase II Clinical Trials
- Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Bayesian design of noninferiority trials for medical devices using historical data
- An empirical Bayes method for multivariate meta-analysis with an application in clinical trials
Cites work
- A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models
- Bayesian design of noninferiority trials for medical devices using historical data
- Bayesian sample size determination for binomial proportions
- Bayesian survival analysis
- Bayesianly justifiable and relevant frequency calculations for the applied statistician
- Sampling and Bayes' Inference in Scientific Modelling and Robustness
Cited in
(6)- On efficient posterior inference in normalized power prior Bayesian analysis
- Discussion of ``Optimal test procedures for multiple hypotheses controlling the familywise expected loss by Willi Maurer, Frank Bretz, and Xiaolei Xun
- The scale transformed power prior for use with historical data from a different outcome model
- Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Normalized power prior Bayesian analysis
This page was built for publication: Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2912356)
